Currently set to Index
Currently set to Follow
search
ask age2b
CART

News

July 14, 2022
0
0
Partial Reprogramming Rejuvenates Human Cells by 30 Years
By AGE2B team
Exposing fibroblasts to the Yamanaka factors for exactly 13 days has yielded substantial results. Researchers from the Reik lab at the Babraham Institute have used the four Yamanaka reprogramming factors (OSKM) in order to epigenetically rejuvenate cells by 30 years, according to one epigenetic clock. Reprogramming just beyond the threshold Previous experiments have shown that […]
Read more
July 14, 2022
0
0
Using Young Stem Cells to Restore Old Stem Cells
By AGE2B team
The restored cells regain many, but not all, of their youthful abilities. In a study published in Aging, researchers have found that younger hematopoietic cells can restore older hematopoietic cells through microvesicles, which are facilitators of intercellular communication. Placing young and old together To begin their experiment, the researchers placed equal amounts of young and old […]
Read more
July 14, 2022
0
0
Getting Proteins Right to Live Longer
By AGE2B team
The accuracy of protein synthesis appears to be a critical part of lifespan in model organisms. Changing a single amino acid in a single protein boosts the fidelity of protein synthesis, and that is enough to increase lifespan in a variety of organisms, according to new research [1]. Proofreading proteins The loss of proteostasis is one […]
Read more
July 14, 2022
0
0
First Multi-Cancer Blood Test Available Now
By AGE2B team
This multi-cancer screening tool works in conjunction with specialized diagnostics. Biotech company GRAIL made history earlier this month when it introduced the first commercially available multi-cancer blood test. The test is based on analyzing tumor DNA in circulation and could be a game-changer in the field of cancer diagnostics, especially if the company continues to improve […]
Read more
July 14, 2022
0
0
New CRISPR Technology Allows Turning Genes Off and On Again
By AGE2B team
Directly affecting methylation sites across the genome allows for precise targeting of epigenetic changes. A new technique allows researchers to turn epigenetic methylation off and back on again, thus allowing the silencing and unsilencing of certain genes. A CRISPR breakthrough CRISPR/Cas9 is a well-known technology for editing the genome, but its potential for epigenetic editing had never […]
Read more
July 14, 2022
0
0
Plasma Exchange Alleviates Alzheimer’s in a Human Trial
By AGE2B team
Albumin seems to drain away the amyloid beta associated with Alzheimer’s. New results from the AMBAR trial show that plasma exchange leads to statistically significant functional and cognitive improvements in patients with mild to moderate Alzheimer’s [1]. As our readers surely know, the world is spending much more resources on fighting the diseases of aging than […]
Read more
July 14, 2022
0
0
Yamanaka Factors and Making Old Cells Young
By AGE2B team
Aging is not a one-way process thanks to partial cellular reprogramming. Today, we chronicle the progress of partial cellular reprogramming and discuss how this powerful treatment may be able to reprogram cells back into a youthful state, at least partially reversing epigenetic alterations, one of the proposed reasons we age. We have created an introduction video […]
Read more
July 14, 2022
0
0
What is Neuralink?
By AGE2B team
Put simply, Neuralink is an attempt to develop the first true mind-machine interface. The Neuralink company, which is owned by Elon Musk, has been trying to develop this interface for a number of years, and it aims to explore how technological augmentation might expand and improve upon the human brain. Neuralink is also being developed with medical conditions in […]
Read more

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.